구조모아 (StructureMoa)항암 chemical structure spider web
방문타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-6 · 마지막 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | doxorubicin hydrochloride (doxorubicin hydrochloride) Prescient Therapeutics, Ltd.·Lymphoma 218 trials·t½ 78.4 days |
|---|---|
Overview Program | doxorubicin hydrochloride |
Overview Company | Prescient Therapeutics, Ltd. |
Overview Modality | ANTIBODY |
Overview Target | Lymphoma |
Overview Indication | Breast Neoplasms; Breast Cancer |
Overview Phase | PHASE_3 |
Overview Status | RECRUITING |
Overview Content status | Limited Data |
Overview Data Confidence | Data Confidence · Low |
Overview Development Signal | Development Signal · Emerging |
Overview Approval status | Investigational |
MoA Mechanism | target multiple pathway |
MoA Biomarker | HER2-positive breast cancer models, including cell lines (CD44 high |
PK/PD Half-life | 78.4 days |
PK/PD Species | Mouse |
PK/PD Animal (cat.) | Mouse, In vitro |
PK/PD Experiment | pharmacokinetic |
Toxicology Species | Mouse |
Toxicology Animal (cat.) | Mouse, In vitro |
Toxicology Major finding | Tailoring pH-responsive charge-conversional interfaces in ionizable lipid-based nanoliposomes for synchronized co-delivery and synergistic therapy of triple-negative breast cancer.. Combination chemotherapy is often limited by the distinct physicochemical properties and intracellular behaviors of individual drugs. This limitation leads to poorly coordinated delivery in tumor tissues. In this study… |
Clinical Safety signal | Tailoring pH-responsive charge-conversional interfaces in ionizable lipid-based nanoliposomes for synchronized co-delivery and synergistic therapy of triple-negative breast cancer.. Combination chemotherapy is often limited by the distinct physicochemical properties and intracellular behaviors of individual drugs. This limitation leads to poorly coordinated delivery in tumor tissues. In this study… |
Clinical Selected reported efficacy | ORR 95% |
Clinical Reported ORR | 95.0% |
Clinical Result source | ClinicalTrials.gov NCT03677141 |
Clinical Program phase | PHASE_3 |
Clinical Trial activity | No active/completed counts |
Clinical Trial ref | NCT03677141 |
타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-6 · 마지막 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | doxorubicin hydrochloride (doxorubicin hydrochloride) Prescient Therapeutics, Ltd.·Lymphoma 218 trials·t½ 78.4 days |
|---|---|
Overview Program | doxorubicin hydrochloride |
Overview Company | Prescient Therapeutics, Ltd. |
Overview Modality | ANTIBODY |
Overview Target | Lymphoma |
Overview Indication | Breast Neoplasms; Breast Cancer |
Overview Phase | PHASE_3 |
Overview Status | RECRUITING |
Overview Content status | Limited Data |
Overview Data Confidence | Data Confidence · Low |
Overview Development Signal | Development Signal · Emerging |
Overview Approval status | Investigational |
MoA Mechanism | target multiple pathway |
MoA Biomarker | HER2-positive breast cancer models, including cell lines (CD44 high |
PK/PD Half-life | 78.4 days |
PK/PD Species | Mouse |
PK/PD Animal (cat.) | Mouse, In vitro |
PK/PD Experiment | pharmacokinetic |
Toxicology Species | Mouse |
Toxicology Animal (cat.) | Mouse, In vitro |
Toxicology Major finding | Tailoring pH-responsive charge-conversional interfaces in ionizable lipid-based nanoliposomes for synchronized co-delivery and synergistic therapy of triple-negative breast cancer.. Combination chemotherapy is often limited by the distinct physicochemical properties and intracellular behaviors of individual drugs. This limitation leads to poorly coordinated delivery in tumor tissues. In this study… |
Clinical Safety signal | Tailoring pH-responsive charge-conversional interfaces in ionizable lipid-based nanoliposomes for synchronized co-delivery and synergistic therapy of triple-negative breast cancer.. Combination chemotherapy is often limited by the distinct physicochemical properties and intracellular behaviors of individual drugs. This limitation leads to poorly coordinated delivery in tumor tissues. In this study… |
Clinical Selected reported efficacy | ORR 95% |
Clinical Reported ORR | 95.0% |
Clinical Result source | ClinicalTrials.gov NCT03677141 |
Clinical Program phase | PHASE_3 |
Clinical Trial activity | No active/completed counts |
Clinical Trial ref | NCT03677141 |
추천 비교
추천 비교